Sanofi and Regeneron acknowledged that testing their inflammatory disease blockbuster Dupixent in chronic obstructive pulmonary disease (COPD) was likely to be high-risk when they launched phase 3 ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

The drug is taken by more than a million patients around the world, Regeneron Chief Executive Leonard Schleifer told analysts on the company's earnings call. "Regarding the ongoing launch in COPD ...

Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...

have fueled the top line for Sanofi and Regeneron. SNY and REGN are working to expand the drug’s label further. The FDA earlier approved Dupixent for chronic obstructive pulmonary disease (COPD).

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD). The ...

Dupixent sales topped $15 billion in 2024, with strong COPD launch and Phase 3 trials ... billion (+23% YoY), annualizing over $15 billion. Regeneron’s total addressable commercial market ...

Based on genetic data linking IL-33 with increased risk of COPD and Phase 2 results, Regeneron’s next innovation in COPD offers potential for benefit in a broader population, including former ...

Regeneron collaborates with Truveta and leading ... The recent approval and launch in chronic obstructive pulmonary disease (COPD) has had a successful start, with coverage secured from the ...